Influenza Vaccine Post Allogeneic Transplant



Status:Terminated
Conditions:Cancer, Influenza, Blood Cancer
Therapuetic Areas:Immunology / Infectious Diseases, Oncology
Healthy:No
Age Range:Any
Updated:12/30/2017
Start Date:September 2010
End Date:June 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?

Study Design:

This is a randomized, single center study to evaluate immune responses to the seasonal
influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who
receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy
adult volunteers will be recruited as controls to confirm immune response to a single
influenza vaccine.


Inclusion Criteria:

- Patient Population

- HSCT recipients who are greater than 60 days post transplant.

- Age 6 months and older who are greater than 60 days post post allogeneic
hematopoietic cell transplant

- Show neutrophil recovery, platelet count > 50,000/mm3 (may be transfused), no
known disease relapse

- No history of previous allergic reaction to influenza vaccine, known egg allergy
or Guillan-Barre Syndrome

- No flu vaccine in previous 4 months, no Campath in previous 6 months, no
intravenous immune globulin (IVIG) in previous 3 months

- Controls:

- Age 18 to 50 years

- No history of previous allergic reaction to influenza vaccine, known egg allergy
or Guillan-Barre Syndrome

- No flu vaccine in previous 4 months
We found this trial at
1
site
Masonic Cancer Center at University of Minnesota
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
612-624-2620
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials